Parabilis Medicines has left the private-company chapter behind and is now a public Helicon-peptide developer whose equity is priced as a platform, not as a single rare-tumor experiment. The June listing and the Regeneron collaboration arrived in the same quarter, converting a decade of intracellular-peptide work into a balance sheet that can fund a registrational desmoid program without a near-term raise. Cash at mid-year stood at $1.1 billion. That stockpile is the reason the investment debate is about probability and scope rather than survival.
The market has already more than doubled the $20 offering price, which means a large share of the Helicon story is already in the quote. Early desmoid activity is the clinical anchor, with a reported 74% objective response rate in the evaluable early-stage set, against an approved gamma-secretase standard that posted a lower response rate in its own registrational work. Regeneron paid $50 million up front and bought stock in the offering, which is real external validation and also a reminder that the partner, not Parabilis, owns development of the conjugate program. The tension is simple. The lead asset still sits in an open-label study, while the enterprise value already treats the modality as substantially de-risked.
Second-quarter spending rose as the company hired into a public-company cost base and pushed zolucatetide across more Wnt-driven cohorts. Net loss widened to $52.5 million, which is the cost of that acceleration rather than a surprise miss. The next several months decide whether the February data cut at the European oncology congress and a year-end FDA discussion support a first-half 2027 Phase 3 start, or whether a larger and more mature desmoid set compresses the response rate that the listing priced in. Does the Helicon story still hold when the desmoid file has to look like a registrational program rather than a promising expansion cohort?